<SEC-DOCUMENT>0001140361-23-007712.txt : 20230221
<SEC-HEADER>0001140361-23-007712.hdr.sgml : 20230221
<ACCEPTANCE-DATETIME>20230221060243
ACCESSION NUMBER:		0001140361-23-007712
CONFORMED SUBMISSION TYPE:	SC 13D/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230221
DATE AS OF CHANGE:		20230221

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-52399
		FILM NUMBER:		23645088

	BUSINESS ADDRESS:	
		STREET 1:		SPACES SOUTH DOCKLANDS, BLOCK C
		STREET 2:		77 SIR JOHN ROGERSON'S QUAY
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		SPACES SOUTH DOCKLANDS, BLOCK C
		STREET 2:		77 SIR JOHN ROGERSON'S QUAY
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sarissa Capital Management LP
		CENTRAL INDEX KEY:			0001577524
		IRS NUMBER:				900924432
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		660 STEAMBOAT ROAD
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
		BUSINESS PHONE:		203-302-2330

	MAIL ADDRESS:	
		STREET 1:		660 STEAMBOAT ROAD
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13D/A
<SEQUENCE>1
<FILENAME>ny20006859x25_sc13da.htm
<DESCRIPTION>SC 13D/A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions
         Document created using Broadridge PROfile 23.1.2.5118
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center">
    <div>
      <div style="text-align: center;"><font style="font-size: 14pt; font-family: 'Times New Roman',Times,serif; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">UNITED


          STATES<br>
          SECURITIES AND EXCHANGE COMMISSION</font><br>
        <font style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: normal; font-variant: normal; text-transform: none;">Washington, D.C. 20549</font></div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SCHEDULE 13D</div>
      <div><br>
      </div>
      <div style="text-align: center;">Under the Securities Exchange Act of 1934</div>
      <div style="text-align: center;">(Amendment No. 10)*<br>
        <br>
      </div>
      <br>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zbf255ffd2a924c6d9a087144c2084f15" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">Amarin Corporation plc</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: center;">(Name of Issuer)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">Ordinary Shares, par value 50 pence per share</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: center;">(Title of Class of Securities)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">023111206</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: center;">(CUSIP Number)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: center;">Mark DiPaolo</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: center;">Senior Partner, General Counsel</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: center;">Sarissa Capital Management LP</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: center;">660 Steamboat Road</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: center;">Greenwich, CT 06830</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">203-302-2330</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: center;">(Name, Address and Telephone Number of Person</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: center;">Authorized to Receive Notices and Communications)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">February 17, 2023</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: center;">(Date of Event which Requires Filing of this Statement)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify;">If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g),
        check the following box. &#9744;</div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="font-weight: bold;">Note:</font>&#160; Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies
        are to be sent.</div>
      <div>&#160;</div>
      <div>*The remainder of this cover page shall be filled out for a reporting person&#8217;s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures
        provided in a prior cover page.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">The information required on the remainder of this cover page shall not be deemed to be &#8220;filed&#8221; for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that
        section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).</div>
      <div>
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify;">
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z9502dbd386434ccf800cc42628184b83" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 49.34%; vertical-align: top;">
                <div style="font-family: 'Times New Roman',Times,serif;">CUSIP No. 023111206</div>
              </td>
              <td style="width: 50.66%; vertical-align: top;">
                <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">Page <font class="BRPFPageNumber">2</font> of 4 Pages</div>
              </td>
            </tr>
            <tr>
              <td colspan="2" style="width: 100%; vertical-align: top;">
                <div style="text-align: center;">SCHEDULE 13D</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="text-align: justify;">This Amendment No. 10 to Schedule 13D (&#8220;Amendment No. 10&#8221;) relates to American Depositary Shares (&#8220;ADS(s)&#8221;), each ADS representing one ordinary share, par value 50 pence per share (the &#8220;Ordinary Shares&#8221;), issued by
        Amarin Corporation plc, a company incorporated under the laws of England and Wales (the &#8220;Issuer&#8221;), and amends the initial statement on Schedule 13D filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on January 24, 2022 (the &#8220;Initial
        Schedule 13D&#8221;), as amended by Amendment No. 1 to Schedule 13D filed on June 3, 2022, Amendment No. 2 to Schedule 13D filed on June 16, 2022, Amendment No. 3 to Schedule 13D filed on October 11, 2022, Amendment No. 4 to Schedule 13D filed on January
        11, 2023, Amendment No. 5 to Schedule 13D filed on January 19, 2023, Amendment No. 6 to Schedule 13D filed on February 8, 2023, Amendment No. 7 to Schedule 13D filed on February 10, 2023, Amendment No. 8 to Schedule 13D filed on February 14, 2023,
        and Amendment No. 9 to Schedule 13D filed on February 15, 2023 (the Initial Schedule 13D as so amended, the &#8220;Schedule 13D&#8221;). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the
        Schedule 13D.</div>
      <div>&#160;</div>
      <div style="text-align: justify;">This Amendment No. 10 is being filed to amend Item 4 and Item 7 as follows:</div>
      <div>&#160;</div>
      <div><font style="font-weight: bold;">Item 4.&#160; Purpose of Transaction. </font>Item 4 of the Schedule 13D is hereby amended to include the following:</div>
      <div>&#160;</div>
      <div style="text-align: justify;">On February 17, 2023, Sarissa Capital issued the press release attached as Exhibit 13 hereto.</div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="font-weight: bold;">Item 7.&#160; Material to Be Filed as Exhibits. </font>Item 7 of the Schedule 13D is hereby amended to include the following:</div>
      <div>&#160;</div>
      <div>Exhibit 13 &#8211; Press Release, February 17, 2023</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div>
        <div style="text-align: justify;">
          <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 49.34%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman',Times,serif;">CUSIP No. 023111206</div>
                </td>
                <td style="width: 50.66%; vertical-align: top;">
                  <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">Page 3<font class="BRPFPageNumber"></font> of 4 Pages</div>
                </td>
              </tr>
              <tr>
                <td colspan="2" style="width: 100%; vertical-align: top;">
                  <div style="text-align: center;">SCHEDULE 13D</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">SIGNATURE</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.</div>
      <div><br>
      </div>
      <div>Dated: February 21, 2023</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zabb36dc242ad406eb4bad71e65372cf0" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td colspan="2" style="vertical-align: top;">
              <div>SARISSA CAPITAL MANAGEMENT LP</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Mark DiPaolo</div>
            </td>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">
              <div>Name: Mark DiPaolo</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">
              <div>Title: Senior Partner, General Counsel</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Alexander J. Denner</div>
            </td>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top;">
              <div>Alexander J. Denner</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Louis Sterling III</div>
            </td>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top;">
              <div>Louis Sterling III</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div>
        <div style="text-align: justify;">
          <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 49.34%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman',Times,serif;">CUSIP No. 023111206</div>
                </td>
                <td style="width: 50.66%; vertical-align: top;">
                  <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">Page <font class="BRPFPageNumber">4</font> of 4 Pages</div>
                </td>
              </tr>
              <tr>
                <td colspan="2" style="width: 100%; vertical-align: top;">
                  <div style="text-align: center;">SCHEDULE 13D</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">INDEX TO EXHIBITS</div>
      <div><br>
      </div>
      <div><a href="ny20006859x25_ex13.htm">Exhibit 13</a> &#8211; Press Release, February 17, 2023</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
      <br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13
<SEQUENCE>2
<FILENAME>ny20006859x25_ex13.htm
<DESCRIPTION>EXHIBIT 13
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions
         Document created using Broadridge PROfile 23.1.2.5118
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div>
      <div style="text-align: right; font-weight: bold;">EXHIBIT 13</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">SARISSA CAPITAL URGES AMARIN SHAREHOLDERS TO VOTE FOR CHANGE AND REMAKE AMARIN FOR SHAREHOLDERS</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">Amarin Deludes Shareholders by Presenting an Alternative Reality Where the Truth Does Not Matter</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">Sarissa Believes that Shareholders Have Suffered Long Enough from the Nightmare under the Current Regime and Should Vote &#8220;FOR&#8221; Change at Amarin</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Greenwich, CT, February 17, 2023 &#8211; Sarissa Capital Management LP (&#8220;Sarissa&#8221;) today issued a presentation detailing the dire need for change at Amarin Corporation plc (NASDAQ: AMRN) accessible at the link below:</div>
      <div><br>
      </div>
      <div><font style="font-weight: bold;">Presentation:</font> <u>https://freeamarin.com/wp-content/pdfs/vote-for-change.pdf</u></div>
      <div><br>
      </div>
      <div>Amarin shareholders face an important decision at our upcoming shareholder meeting. Amarin has a uniquely valuable asset in Vascepa/Vazkepa, a drug that can meaningfully reduce cardiovascular events in patients and save significant resources for
        health systems worldwide. The value of Vascepa, however, continues to be wasted by the company due to its mismanagement and poor capital allocation decisions. We cannot afford to allow the current regime to destroy further shareholder value. Our
        slate, including Sarissa candidates that helped turn around The Medicines Company until its ultimate sale for nearly $10 billion, has the qualifications and the experience to help guide Amarin through this critical period.</div>
      <div><br>
      </div>
      <div>We urge all shareholders to vote &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the Sarissa Nominees and &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the removal of Chairman Per Wold-Olsen on or prior to the deadline on Tuesday, February 21,
        2023.</div>
      <div><br>
      </div>
      <div>You can vote on the blue proxy card or the white proxy card but if you want to fully support Sarissa, you must make sure that all &#8220;<font style="font-weight: bold;">FOR</font>&#8221; boxes are marked on your proxy card (blue or white) before you submit
        it.</div>
      <div><br>
      </div>
      <div>If you have any questions on how to vote, we recommend that you contact Sarissa&#8217;s proxy solicitor, D.F. King, by calling (800) 331-7024 or emailing <u>AMRN@dfking.com</u>.</div>
      <div><br>
      </div>
      <div>Visit our website at <u>www.freeamarin.com</u><font style="color: #0563C1;">&#160;</font>for helpful information about Sarissa and the need for change at Amarin.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">IF YOU ALREADY VOTED &#8220;FOR&#8221; ALL PROPOSALS AND SUBMITTED YOUR BLUE PROXY CARD, THERE IS NOTHING ELSE YOU NEED TO DO TO SUPPORT SARISSA&#8217;S NOMINEES. YOU DO NOT NEED TO VOTE AGAIN.</div>
      <div><br>
      </div>
      <div>The General Meeting of Amarin shareholders is scheduled for February 28, 2023, BUT TO MAKE SURE YOUR VOTE COUNTS, <font style="font-weight: bold;"><u>SUBMIT YOUR VOTE ON OR BEFORE TUESDAY, FEBRUARY 21, 2023</u></font>.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div>&#160;</div>
      <div style="font-weight: bold;">Additional Information</div>
      <div><br>
      </div>
      <div>Sarissa Capital Management LP (&#8220;Sarissa Capital&#8221;), together with other participants, filed a definitive proxy statement and an accompanying blue proxy card with the SEC on January 31, 2023, in connection with the solicitation of shareholders of
        Amarin Corporation plc (the &#8220;Company&#8221;) at the general meeting of the Company for the election of Sarissa Capital&#8217;s slate of highly-qualified nominees (the &#8220;General Meeting&#8221;). Shareholders are advised to read the definitive proxy statement and other
        relevant documents related to the General Meeting as they contain important information.</div>
      <div><br>
      </div>
      <div>The definitive proxy statement and other relevant documents are available at no charge on the SEC&#8217;s website at <u>www.sec.gov</u> and at <u>www.freeamarin.com</u>. The definitive proxy statement and other relevant documents are also available
        at no charge by directing a request to Sarissa Capital&#8217;s proxy solicitor, D.F. King &amp; Co., Inc., 48 Wall Street, New York, New York 10005 (Shareholders can call toll-free: (800) 331-7024).</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7d0e7aaa022d417ea70b2cc82d99a1fc" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt; vertical-align: top;">Contact:</td>
            <td style="width: auto; vertical-align: top;">
              <div>Jean Puong<br>
                Sarissa Capital Management LP<br>
                info@sarissacap.com</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div>#FreeAmarin</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
